Strong growth for all Terumo's businesses
This article was originally published in Clinica
The Japanese company Terumo described the year as being one of "considerable progress", despite unstable exchange rates, further regulation of medical fees and increased competition. The company has ambitious plans to boost turnover to become a ¥00 billion ($1.5 billion) company within three years. In the year ended March 31 1997, the company's annual sales rose 14% to Yen138 billion ($1.1 billion), and net income rocketed 289% to Yen12.5 billion.
You may also be interested in...
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.